rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2010-6-4-550-557rpcardio-887Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИIMPLICATION OF THE FIXED COMBINATIONS IN THE HYPERTENSION TREATMENTМЕСТО КОМБИНИРОВАННОЙ ТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ФИКСИРОВАННЫХ КОМБИНАЦИЙ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИКобалаваЖ. Д.KobalavaZ. D.

профессор, д.м.н., заведующая кафедрой кардиологии и клинической фармакологии факультета повышения квалификации 

Москва, 117198, ул. Миклухо-Маклая, д.6

Miklukcho-Maklaya ul. 6, Moscow, 117198

КотовскаяЮ. В.KotovskayaJ. V.

профессор, д.м.н., профессор кафедры кардиологии и клинической фармакологии факультета повышения квалификации

Москва, 117198, ул. Миклухо-Маклая, д.6

Miklukcho-Maklaya ul. 6, Moscow, 117198

kotovskaya@bk.ruРоссийский университет дружбы народовРоссияPeoples’ Friendship University of RussiaRussian Federation20101901201664550557Copyright © Kobalava Z.D., Kotovskaya J.V., 20162016Кобалава Ж.Д., Котовская Ю.В.Kobalava Z.D., Kotovskaya J.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/887

The role of fixed combinations in the hypertension (HT) treatment is discussed. Theoretical and practical aspects of combination therapy, principles of rational combination therapy are present. Current guidelines on the use of fixed dose combinations, including start antihypertensive therapy are analyzed. Classification of combinations, advantages and limitations of some of them implementation are also presented. Significance of beta-blocker bisoprolol and thiazide diuretic hydrochlorothiazide fixed combination (Lodoz) is shown in HT treatment.

Обcуждается место фиксированных комбинаций в лечении артериальной гипертонии (АГ). Рассмотрены теоретические и практические аспекты комбинированной терапии, принципы рациональной комбинированной терапии. Проанализированы современные рекомендации по использованию фиксированных комбинаций, в том числе в качестве стартовой антигипертензивной терапии. Приведена классификация комбинаций и проанализированы преимущества и ограничения использования некоторых из них. Освещено место фиксированной комбинации бета-адерноблокатора бисопролола и тиазидного диуретика гидрохлортиазида (Лодоза) в лечении АГ.

артериальная гипертониякомбинированная терапияфиксированные комбинациибисопрололгидрохлортиазидarterial hypertensioncombined therapyfixed combinationbisoprololhydrochlorthiazideReferencesДиагностика и лечение артериальной гипертензии, Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2: 1-32.Диагностика и лечение артериальной гипертензии, Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008; 7(6) приложение 2: 1-32.Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42(6):1206-1252Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6):1105-1187Mancia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25(6):1105-1187Mancia G., Laurent S.,Agabiti-Rosei E. et al.Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18(6):308-47.Mancia G., Laurent S.,Agabiti-Rosei E. et al.Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009;18(6):308-47.GradmanA.H., Basile J.N., Carter B.L., Bakris G.L. on behalf oftheAmerican Society ofHypertension Writing Group. Combination therapy in hypertension. ASH Position Article. J Am Soc Hypertens 2010;4(1): 42–50GradmanA.H., Basile J.N., Carter B.L., Bakris G.L. on behalf oftheAmerican Society ofHypertension Writing Group. Combination therapy in hypertension. ASH Position Article. J Am Soc Hypertens 2010;4(1): 42–50Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427-35.Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326(7404):1427-35.Neaton J.D., Grimm R.H. Jr., Prineas R.J. et al. Treatment of Mild Hypertension Study. JAMA 1993;270(6):713-24.Neaton J.D., Grimm R.H. Jr., Prineas R.J. et al. Treatment of Mild Hypertension Study. JAMA 1993;270(6):713-24.ALLHAT Officers and Coordinators fortheALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–97.ALLHAT Officers and Coordinators fortheALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–97.Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principalresults oftheHypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351(9118):1755–62.Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principalresults oftheHypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351(9118):1755–62.Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):995–1003.Dahlof B., Devereux R.B., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359(9311):995–1003.Dickerson J.E., Hingorani A.D., Ashby M.J. et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353(9169):2008-13.Dickerson J.E., Hingorani A.D., Ashby M.J. et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353(9169):2008-13.Mourad J., Waeber B., Zinnad F. et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004;22(12):2379–86.Mourad J., Waeber B., Zinnad F. et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004;22(12):2379–86.Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials. Am J Med 2009;122(3):290–300.Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 Trials. Am J Med 2009;122(3):290–300.Sica D.A. Rationale forfixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62(3):443–62Sica D.A. Rationale forfixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62(3):443–62Fung V., Huang J., Brand R. et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29(5): 972–84.Fung V., Huang J., Brand R. et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29(5): 972–84.Dunbar-Jacob. NationalHeart, Lung and Blood Institute Implementation Conference 2009.Dunbar-Jacob. NationalHeart, Lung and Blood Institute Implementation Conference 2009.Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. et al. Fixeddose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713–719.Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. et al. Fixeddose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713–719.Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363(9426):2049–51.Weber M.A., Julius S., Kjeldsen S.E. et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363(9426):2049–51.Mancia G., Messerli F., Bakris G. et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50(2):299–305.Mancia G., Messerli F., Bakris G. et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension 2007; 50(2):299–305.Jamerson K., Bakris G.L., Dahlof B. et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16(2):80–86.Jamerson K., Bakris G.L., Dahlof B. et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16(2):80–86.Feldman R.D., Zou G.Y., Vandervoort M.K. et al. A simplified approach to the treatment of uncomplicated hypertension: a clusterrandomized, controlled trial. Hypertension 2009;53(4): 646–653.Feldman R.D., Zou G.Y., Vandervoort M.K. et al. A simplified approach to the treatment of uncomplicated hypertension: a clusterrandomized, controlled trial. Hypertension 2009;53(4): 646–653.Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manage Care 2000;9(9 Suppl):2–6.Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manage Care 2000;9(9 Suppl):2–6.Egan B.M. Fixed-dose combinations and hypertension control in community-based practices: application of the ‘‘keep-it-simple’’ principle. Hypertension 2009; 53(4):598–599.Egan B.M. Fixed-dose combinations and hypertension control in community-based practices: application of the ‘‘keep-it-simple’’ principle. Hypertension 2009; 53(4):598–599.Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–59.Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–59.Izzo R., de Simone G., Chinali M. et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care 2009;32(5):845–50.Izzo R., de Simone G., Chinali M. et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care 2009;32(5):845–50.The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362(16): 1477-90.The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362(16): 1477-90.Frishman W.H., Brizzynski B.S., Coulson L.R. et al. A multifactorial tri￾al design to assess cjmbination therapy in hypertension: treatment with Bissoprolol andHydrochlorothiazide. Arch Intern Med 1994; 154(13): 1461-8.Frishman W.H., Brizzynski B.S., Coulson L.R. et al. A multifactorial tri￾al design to assess cjmbination therapy in hypertension: treatment with Bissoprolol andHydrochlorothiazide. Arch Intern Med 1994; 154(13): 1461-8.Frishman W.H., Burris J.F., Mroczek W.J. et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35(2):182-8.Frishman W.H., Burris J.F., Mroczek W.J. et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35(2):182-8.Lewin A.J., Lueg M.C., Targum S., Cardenas P. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. Clin Cardiol 1993;16(10):732-6.Lewin A.J., Lueg M.C., Targum S., Cardenas P. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. Clin Cardiol 1993;16(10):732-6.Benetos A., Cosoli S., Safavian A. et al. Efficacy, safety and effects on quality of life of Bisoprolol/Hydrochlorothiazide versus Amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140(4): e14.Benetos A., Cosoli S., Safavian A. et al. Efficacy, safety and effects on quality of life of Bisoprolol/Hydrochlorothiazide versus Amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140(4): e14.Rejnmark L., Vestergaard P., Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium channel blockers is associated with a reduced fracture risk: a nationwide case–control study.JHypertens2006; 24(3):581–589Rejnmark L., Vestergaard P., Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium channel blockers is associated with a reduced fracture risk: a nationwide case–control study.JHypertens2006; 24(3):581–589Prisant L.M., NeutelJ.M., PapademetriouV. et al. Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies. Am J Ther 1998;5(5):313-21.Prisant L.M., NeutelJ.M., PapademetriouV. et al. Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies. Am J Ther 1998;5(5):313-21.Papademetriou V., Neutel J., Naravan P. et al. Comparison of Bisoprolol and low doseHydrochlorothiazide combination with Losartan, alone or in combination with Hydrochlorothiazide, in the treatment of hypertension: a double blind, randomized, placebo controlled trial. Car￾diovasc Rev Rep 1999;19(12):19-28.Papademetriou V., Neutel J., Naravan P. et al. Comparison of Bisoprolol and low doseHydrochlorothiazide combination with Losartan, alone or in combination with Hydrochlorothiazide, in the treatment of hypertension: a double blind, randomized, placebo controlled trial. Car￾diovasc Rev Rep 1999;19(12):19-28.Prisant L.M., Weir M.R., Frishmanwh et al. Self reported Sexual Dysfunction in Men and Woman Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999;1(1):22-26.Prisant L.M., Weir M.R., Frishmanwh et al. Self reported Sexual Dysfunction in Men and Woman Treated With Bisoprolol, Hydrochlorothiazide, Enalapril, Placebo, or Bisoprolol/Hydrochlorothiazide. J Clin Hypertens (Greenwich) 1999;1(1):22-26.

The authors declare that there are no conflicts of interest present.